Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
Cells · 04.10.2023 · 12 (19) · 2404
DOI: 10.3390/cells12192404 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 04.10.2023. Verfasst von Jensen Abascal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCI NIH HHS, UCLA Tumor Immunology Institutional Training Grant USHHS Ruth L. Kirschstein Institutional National Research Service Award.
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) remains one of the leading causes of death worldwide. While NSCLCs possess antigens that can potentially elicit T cell responses, defective tumor antigen presentation and T cell activation hinder host anti-tumor immune responses. The NSCLC tumor microenvironment (TME) is composed of cellular and soluble mediators that can promote or combat tumor growth. The composition of the TME plays a critical role in promoting tumorigenesis and dictating anti-tumor immune responses to immunotherapy. Dendritic cells (DCs) are critical immune cells that activate anti-tumor T cell responses and sustain effector responses. DC vaccination is a promising cellular immunotherapy that has the potential to facilitate anti-tumor immune responses and transform the composition of the NSCLC TME via tumor antigen presentation and cell–cell communication. Here, we will review the features of the NSCLC TME with an emphasis on the immune cell phenotypes that directly interact with DCs. Additionally, we will summarize the major preclinical and clinical approaches for DC vaccine generation and examine how effective DC vaccination can transform the NSCLC TME toward a state of sustained anti-tumor immune signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
- Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095-1690, USA.
Förderung
- BLRD VA
- NCI NIH HHS
- UCLA Tumor Immunology Institutional Training Grant USHHS Ruth L. Kirschstein Institutional National Research Service Award
- California Institute for Regenerative Medicine
Zitieren
APA
Abascal, J., Oh, M. S., Liclican, E. L., Dubinett, S. M., Salehi-Rad, R., & Liu, B. (2023). Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment. Cells, 12(19), 2404. https://doi.org/10.3390/cells12192404
Vancouver
Abascal J, Oh MS, Liclican EL, Dubinett SM, Salehi-Rad R, Liu B. Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment. Cells. 2023;12(19):2404. doi:10.3390/cells12192404
BibTeX
@article{Abascal2023,
author = {Abascal, Jensen and Oh, Michael S and Liclican, Elvira L and Dubinett, Steven M and Salehi-Rad, Ramin and Liu, Bin},
title = {Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment},
journal = {Cells},
year = {2023},
volume = {12},
number = {19},
pages = {2404},
doi = {10.3390/cells12192404}
}
EUVIMED